On November 2, 2018 OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, reported that preliminary clinical and immunological data from its ongoing KEYNOTE-695 study, a global, multicenter, registration-directed Phase 2b trial of TAVO in combination with KEYTRUDA for the treatment of metastatic melanoma, were accepted for a late-breaking Poster Presentation at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 7-11, 2018 (Press release, OncoSec Medical, NOV 2, 2018, View Source [SID1234530633]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The details of the Poster Presentation are as follows:
Presentation Title: Initial report of intratumoral tavokinogene telseplasmid with pembrolizumab in advanced melanoma: an approach designed to convert PD-1 antibody progressors into responders.
Author: Atkinson, et. al.
Poster Number: P717
Presentation date: Friday, November 9 and Saturday, November 10, 2018
The late-breaking abstract titles can be found on the conference website here.
KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.